IDIBELL on the media

icabell_-_h2020

Specialised training session for H2020 project managers

On June 21st, the training session “How to support researchers in writing competitive proposals for Horizon 2020” was held at the Duran i Reynals hospital. The course, part of the ICABELL project, was taught by Dr. Sean McCarthy, expert in European funding for research projects.   The session, which had a high degree of attendance, […]

img_20180626_125320_1

New combined treatment shows promise in Hepatocellular Carcinoma

A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival

gusano-2

CRISPR-editing of a single aminoacid make a whole animal more resistant to cisplatin-based chemotherapy

Cisplatin is one of the chemotherapeutic agents more frequently used by oncologists to treat tumors. Cisplatin-based chemotherapy is very efficient but frequently cancer cells adjust its molecular mechanisms to become resistant to cisplatin. The IDIBELL research group “Modeling Human diseases in C. elegans”, led by Julián Cerón, have been using a microscopic worm to investigate […]

galaaecc

Two new AECC grants for IDIBELL researchers

Ernest Nadal and Samuel Gonçalves are awarded research grants to advance in cancer research

img_2217

New discoveries towards the improvement of the immunotherapy treatment of lung cancer

In recent years, immunotherapy has been consolidated as one of the new and principal hopes in the fight against cancer. This therapeutic approach is based on the fact that our immune system is constantly watching the presence of strange presences within the body and fighting them. When a tumor originates, its mutations make cancer cells […]

villanueva_nadal

New drug against of the main types of lung cancer

The clinical application of an inhibitor of the SHP2 protein (also called PTPN11) could be effective, in the near future, in patients affected by one of the main types of lung cancer, the so-called Non-small cell lung cancer (NSCLC). This is the conclusion reached by an international research team including doctors Alberto Villanueva and Ernest […]

limfoma_cells

New epigenetic drug against Mantle Cell Lymphoma

A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of Barcelona, presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL), a type of cancer characterized by […]

franciscociruela

First photoactive drug to fight Parkinson’s disease

Experts from the Institute of Neurosciences of the University of Barcelona (UB), the Bellvitge Biomedical Research Institute (IDIBELL) and Universitat Autònoma de Barcelona (UAB) design the first photoactive drug to fight Parkinson’s disease.

np17-larriba-puigvert

New non-invasive biomarker for diagnosis and prognosis in male sterility

Researchers from the Human Molecular Genetics group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Sara Larriba, have identified a new non-invasive biomarker of the presence of sperm in the testis of azoospermic men, who represent 10% of the cases of male sterility. The work, published in the prestigious international journal Human Reproduction, […]

remab2

Green light to REMAB, a new IDIBELL Spin-Off

REMAB Therapeutics, the new IDIBELL Spin-off, was officially launched by the end of April 2018. The company has doctors Rafael Mañez (IP) and Daniel Bello, from the research group on innate immunity and pathology of the critical patient, as founding partners, together with IDIBELL. REMAB’s main objective is the development of a new molecule for […]